-
公开(公告)号：KR101485162B1
公开(公告)日：2015-01-26
申请号：KR1020100097677
申请日：2010-10-07
Applicant: 한국해양과학기술원
IPC: A61K31/357 , A61P3/04 , A61P3/10
Abstract: 본 발명은 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물에 관한 것으로, 보다 구체적으로는, 남극 지의류인 스테레오카울론 알피넘(Stereocaulon alpinum) 추출물에서 분리된 로바릭산의 염인 소듐 로바레이트를
유효성분으로 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물과 기능성 식품에 관한 것이다. 본 발명에 따른 소듐 로바레이트는 수용성 화합물로서 적용이 용이하며, 단백질 타이로신포스파타제 1B 저해활성이 매우 뛰어나며, 단백질타이로신탈인산화효소 family 중 PTP1B에만 선택적으로 작용하는바, 실질적인 PTP1B 저해제로 이형당뇨치료에 이용가능한바, 당뇨병 및 비만의 예방 또는 치료에 효과적이다.-
公开(公告)号：KR101481140B1
公开(公告)日：2015-01-15
申请号：KR1020100097678
申请日：2010-10-07
Applicant: 한국해양과학기술원
IPC: C07D307/88 , C07D307/87 , A61K31/343 , A61P3/04
Abstract: 본 발명은 신규 화합물 로바린을 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물에 관한 것으로, 보다 구체적으로는, 남극 지의류인 스테레오카울론 알피넘(
Stereocaulon alpinum ) 추출물로부터 분리된 화합물로부터 합성한 신규 화합물 로바린을 유효성분으로 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물과, 상기 화합물을 함유하는 기능성 식품에 관한 것이다. 본 발명에 따른 스테레오카울론 알피넘(
Stereocaulon
alpinum ) 유래 로바린은 단백질 타이로신 포스파타제 1B의 저해활성이 뛰어나며, 동물모델에 적용시에도 우수한 항당뇨 효과를 가지는 것으로 확인된바, 당뇨병 및 비만의 예방 또는 치료에 효과적으로 사용될 수 있어 매우 유용하다.-
公开(公告)号：KR101452324B1
公开(公告)日：2014-10-21
申请号：KR1020120082486
申请日：2012-07-27
Applicant: 한국해양과학기술원
IPC: A61K36/09 , A23L29/206 , A61P31/04 , A61P17/18
Abstract: 본 발명은 남극 지의류인 스테레오카울론 알피넘 (
Stereocaulon alpinum) 에서 분리한 항균활성이 뛰어난 화합물에 관한 것으로, 보다 구체적으로는, 스테레오카울론 알피넘 (
Stereocaulon alpinum) 의 추출물에서 분리된 뎁시돈 (depsidone) 형 천연화합물인 로바릭산 (lobaric acid, 화합물 1)과 슈도뎁시돈 (pseudodepsidone) 형 천연화합물인 로바스틴 (lobarstin, 화합물 2), 또는 그의 염을 유효성분으로 함유하는 항균 및 항산화 조성물에 관한 것이다.
본 발명에 따른 조성물은 효과적인 항균 능력을 보이므로 항균 조성물과 세균 감염성 질환이 예방 또는 치료용 약학 조성물 및 기능성 식품에 이용될 수 있으며, 또한 본 발명의 조성물은 효과적인 항산화 효과를 보이므로 항산화 조성물로 제조 및 응용될 수 있다.-
公开(公告)号：KR101354168B1
公开(公告)日：2014-01-24
申请号：KR1020110108223
申请日：2011-10-21
Applicant: 한국해양과학기술원
IPC: C07D307/10 , A61K36/09 , A61K31/34 , A61P3/10 , A61P3/00
Abstract: 본 발명은 단백질 타이로신 탈인산화효소 1B(PTP1B)의 활성을 저해하는 디터펜 푸라노이드 화합물 및 그 용도에 대한 것으로, 보다 상세하게는 남극의 지의류인 추출물인 디터펜 푸라노이드(Diterpene Furanoids), 상기 디터펜 푸라노이드의 제조방법 및 상기 디터펜 푸라노이드를 유효성분으로 함유하는 이형당뇨치료용 약학조성물 및 기능성 식품에 관한 것이다.
-
公开(公告)号：KR1020130098745A
公开(公告)日：2013-09-05
申请号：KR1020120020515
申请日：2012-02-28
Applicant: 한국해양과학기술원
IPC: A61K31/175 , A61K31/17 , A61P1/16 , A61P1/00
CPC classification number: A61K31/165 , A23L33/105 , A23V2002/00 , A61K36/09
Abstract: PURPOSE: A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis is provided to effectively suppress hepatic fibrosis without cytotoxicity to normal hepatocytes using ramalin, thereby effectively preventing or treating hepatic fibrosis and liver cirrhosis. CONSTITUTION: A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. A functional food for preventing or treating hepatic fibrosis or liver cirrhosis contains the compound or a sitologically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis contains a Ramalina terebrata extract containing the compound of chemical formula 1 as an active ingredient.
Abstract translation: 目的：提供一种用于预防或治疗肝纤维化或肝硬化的药物组合物，以有效抑制肝纤维化，而不会对使用马马林的正常肝细胞产生细胞毒作用，从而有效预防或治疗肝纤维化和肝硬化。 构成：用于预防或治疗肝纤维化或肝硬化的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。 用于预防或治疗肝纤维化或肝硬化的功能性食品含有作为活性成分的化合物或其可以可接受的盐。 用于预防或治疗肝纤维化或肝硬化的药物组合物含有含有化学式1化合物作为活性成分的拉马鞭毛霉提取物。
-
Patent Agency Ranking
公开(公告)号：KR1020130043996A
公开(公告)日：2013-05-02
申请号：KR1020110108223
申请日：2011-10-21
Applicant: 한국해양과학기술원
IPC: C07D307/10 , A61K36/09 , A61K31/34 , A61P3/10 , A61P3/00
Abstract: PURPOSE: A diterpene furanoids compound inhibiting a protein tyrosine dephosphorylation enzyme 1B, and the use thereof are provided to have an excellent effect of medical treatment on insulin-independent type-2 diabetes. CONSTITUTION: A Huea coralligera extract has an activity inhibition of a protein tyrosine dephosphorylation enzyme 1B(PTP1B). The Huea coralligera extract is extracted with a solvent selected from the group of water, lower alcohol with 1-4 carbons, and a mixture thereof. The diterpene furanoids compound is represented by chemical formula 1-4. A separation method of a Hueafuranoids compound is represented by the chemical formula 1 or the chemical formula 2. A pharmaceutical composition for the treatment of type-2 diabetes contains the Huea coralligera extract as an active ingredient.
Abstract translation: 目的：抑制蛋白酪氨酸脱磷酸酶1B的二萜类呋喃酮化合物，其用途对胰岛素依赖型2型糖尿病具有优异的医疗效果。 构成：一种胡萝卜提取物具有蛋白酪氨酸脱磷酸酶1B（PTP1B）的活性抑制作用。 用选自水，具有1-4个碳原子的低级醇的溶剂及其混合物萃取胡须珊瑚提取物。 二萜类呋喃类化合物以化学式1-4表示。 类胡萝卜素化合物的分离方法由化学式1或化学式2表示。用于治疗2型糖尿病的药物组合物含有作为活性成分的胡叶藻提取物。
-
公开(公告)号：KR1020140015956A
公开(公告)日：2014-02-07
申请号：KR1020120082486
申请日：2012-07-27
Applicant: 한국해양과학기술원
IPC: A61K36/09 , A23L29/206 , A61P31/04 , A61P17/18
Abstract: The present invention relates to a compound having excellent antibiotic activity, isolated from Stereocaulon alpinum, which is a kind of antarctic lichen, and more particularly, to an antibiotic and antioxidative composition containing, as an active ingredient, lobaric acid (Compound 1) as a depsidone type natural compound and lobarstin as a pseudodepsidone type natural compound, which are isolated from an extract of Stereocaulon alpinum, or salts thereof. The composition according to the present invention exhibits an effective antibiotic ability, and thus can be used for an antibiotic composition, and a pharmaceutical composition and a functional food for preventing or treating infectious diseases. Further, the composition of the present invention exhibits an effective antioxidative effect, and thus can be prepared and applied as an antioxidative composition.
Abstract translation: 本发明涉及一种具有优异的抗生素活性的化合物，它是一种南极地衣，是一种南极地衣，特别是一种抗生素和抗氧化组合物，其含有作为活性成分的洛叶酸（化合物1）作为 取代吡啶酮型天然化合物和洛尔斯坦作为假食蜂星酮型天然化合物，其从Stereocaulon alpinum的提取物中分离，或其盐。 根据本发明的组合物显示出有效的抗生素能力，因此可用于抗生素组合物，以及用于预防或治疗感染性疾病的药物组合物和功能性食品。 此外，本发明的组合物显示出有效的抗氧化作用，因此可以制备和应用为抗氧化组合物。
-
公开(公告)号：KR1020130106045A
公开(公告)日：2013-09-27
申请号：KR1020120027649
申请日：2012-03-19
Applicant: 한국해양과학기술원
IPC: C07C241/04 , C07C243/22 , A61K31/135 , A61Q19/02
CPC classification number: A61K31/198 , A61K8/0287 , A61K8/442 , A61K8/585 , A61K2800/52 , A61Q19/02 , A61Q19/08
Abstract: PURPOSE: A stabilizing method of ramalin is provided to maintain titer in high level and to store ramalin with excellent anti-oxidation and anti-inflammation effect. CONSTITUTION: A stabilizing method of ramalin represented by chemical formula 1 comprises a step of absorbing the ramalin to a hydrophilic porous matrix; a step of reforming the surface of a porous matrix on which the ramalin is absorbed to a hydrophilic surface; and a step of dispersing the porous matrix into an organic solvent. The hydrophilic porous matrix consists of hydrophilic aerogel. The organic solvent is selected from caprylic/capric triglyceride, squalane, silicone oil, mineral oil, vegetable oil, and a mixture thereof.
Abstract translation: 目的：提供拉马林的稳定化方法，以保持高水平的效价，并具有极好的抗氧化和抗炎作用。 构成：用化学式1表示的马来林蛋白的稳定化方法包括将马马林吸收到亲水性多孔基质的步骤; 将马来酸盐吸收到其上的多孔基质的表面改性为亲水性表面的步骤; 以及将多孔基质分散到有机溶剂中的步骤。 亲水性多孔基质由亲水性气凝胶组成。 有机溶剂选自辛酸/癸酸甘油三酯，角鲨烷，硅油，矿物油，植物油及其混合物。
-
公开(公告)号：KR1020120036026A
公开(公告)日：2012-04-17
申请号：KR1020100097678
申请日：2010-10-07
Applicant: 한국해양과학기술원
IPC: C07D307/88 , C07D307/87 , A61K31/343 , A61P3/04
Abstract: PURPOSE: A pharmaceutical composition containing a novel compound, lobarin, is provided to suppress tyrosine phosphatase 1B and to ensure antidiabetic effect. CONSTITUTION: A novel compound, lobarin, is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of extracting Stereocaulon alpinum with methanol; a step of eluting methanol solution by column chromatography; a step of eluting the eluted fraction by reverse-phase high performance liquid chromatography using a acetonitrile(CH_3CN) solution to prepare a fraction containing lobaric acid; a step of dissolving the fraction in solvent and a step of adding NaOH or KOH. A pharmaceutical composition for preventing or treating diabetes or obesity contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有新化合物洛尔林的药物组合物，以抑制酪氨酸磷酸酶1B并确保抗糖尿病作用。 构成：化学式1表示新化合物洛比林。化学式1化合物的制备方法包括：用甲醇提取立体异黄酮的步骤; 通过柱色谱法洗脱甲醇溶液的步骤; 通过使用乙腈（CH 3 CN）溶液的反相高效液相色谱法洗脱洗脱级分以制备含有叶酸的级分的步骤; 将级分溶解在溶剂中的步骤和加入NaOH或KOH的步骤。 用于预防或治疗糖尿病或肥胖症的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。
-
公开(公告)号：KR1020120036025A
公开(公告)日：2012-04-17
申请号：KR1020100097677
申请日：2010-10-07
Applicant: 한국해양과학기술원
IPC: A61K31/357 , A61P3/04 , A61P3/10
Abstract: PURPOSE: A pharmaceutical composition containing sodium lobarate is provided to suppress tyrosine phosphatase 1B and to treat type II diabetes. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes or obesity contains sodium lobarate of chemical formula 1 as an active ingredient. A functional food for preventing or treating diabetes or obesity contains sodium lovarate of chemical formula 1. Sodium lovarate is isolated from Stereocaulon alpinum extract. A method for preparing lovaric acid comprises: a step of extracting dried Stereocaulon alpinum using methanol for 24 hours; a step of distilling the solvent; a step of loading flash column chromatography filled with silicagel(C18); and a step of injecting 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%(v/v) methanol in order to obtain each fraction.
Abstract translation: 目的：提供含有洛乐碱钠的药物组合物，以抑制酪氨酸磷酸酶1B并治疗II型糖尿病。 构成：用于预防或治疗糖尿病或肥胖症的药物组合物含有化学式1的挥发油作为活性成分。 用于预防或治疗糖尿病或肥胖症的功能性食物含有化学式1的乐天酸钠。从立体立体异黄酮提取物中分离出乐果酸钠。 一种制备洛伐克酸的方法包括：使用甲醇提取干燥的立体立体异黄酮24小时的步骤; 蒸馏溶剂的步骤; 加载填充有硅胶（C18）的快速柱色谱的步骤; 以及注入10％，20％，30％，40％，50％，60％，70％，80％，90％和100％（v / v）甲醇的步骤，以获得每个级分。
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.027 seconds)
